Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.

Dec 24, 2023 - 18:00

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.

Read the original article

Tags:

Previous Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Soligenix and Silk Road sign deal for Behçet’s disease treatment rights

Soligenix and Silk Road sign deal for Behçet’s disease ...

May 2, 2023

OCX-063 by OccuRx for Proliferative Vitreoretinopathy (...

Jun 5, 2023

UBC to bolster safety functions with Oracle’s cloud technology

UBC to bolster safety functions with Oracle’s cloud tec...

Aug 2, 2023